Results 21 to 30 of about 4,483 (147)

Medication Related Osteonecrosis of the Jaw: Knowledge, Attitudes and Practice Patterns Among Australian Dental Practitioners

Australian Dental Journal, EarlyView.
ABSTRACT Background Medication related osteonecrosis of the jaw (MRONJ) is a debilitating condition associated with antiresorptive and antiangiogenic therapies. As the use of these medications continues to increase, dental practitioners play a critical role in prevention and management of at‐risk patients. This survey evaluated the awareness, knowledge
Ying Shi Chang, Christopher Friel, Gary Low, Albert Yaacoub, Stephen Clive Cox   +4 more
wiley   +1 more source

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review

Frontiers in Oral Health
IntroductionMedication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone.
Rodolfo Mauceri, Rodolfo Mauceri, Sonia Arduini, Martina Coppini, Martina Coppini, Martina Coppini, Monica Bazzano, Isabel Trujillo, Giuseppina Campisi   +8 more
doaj   +1 more source

Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?

Case Reports in Dentistry, 2016
Objective. The acronym MRONJ has been created in order to identify “Medication-Related Osteonecrosis of the Jaw,” observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw in
Andrea Cassoni, Umberto Romeo, Valentina Terenzi, Marco Della Monaca, Oriana Rajabtork Zadeh, Ingrid Raponi, Maria Teresa Fadda, Antonella Polimeni, Valentino Valentini   +8 more
doaj   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

The Effects of Simulation‐Based Interprofessional Education on Oncology Oral Care Competencies Among Dental and Dental Hygiene Students

European Journal of Dental Education, EarlyView.
ABSTRACT Introduction This study applied simulation‐based interprofessional education (IPE) principles to develop an oncology oral care scenario, with the aim of evaluating the intervention's effects on the IPE core competencies of dental and dental hygiene students before their clinical internships. Materials and Methods Twenty‐eight fifth‐year dental
Shin‐Ru Liao, Pei‐Chen Lin, Ai‐Hua Chang, Kun‐Tsung Lee, Peih‐Ying Lu, Hsiao‐Ling Huang, Ju‐Hui Wu   +6 more
wiley   +1 more source

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source

The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review

Journal of Research in Medical Sciences, 2021
Medication related osteonecrosis of the jaw (MRONJ) is a severe condition affecting the jaws of patients exposed to specific drugs, and is primarily described in patients receiving bisphosphonate (BP) therapy.
Roberto Sacco, Julian Woolley, Julian Yates, Monica Diuana Calasans-Maia, Oladapo Akintola, Vinod Patel   +5 more
doaj   +1 more source

Denosumab discontinuation and fracture risk: getting the balance right

Internal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source

MicroRNA in medication related osteonecrosis of the jaw: a review

Frontiers in Physiology, 2023
Medication related osteonecrosis of the jaw (MRONJ) is a condition caused by inhibition of the osteoclast activity by the anti-resorptive and anti-angiogenic drugs.
Siti Salmiah Mohd Yunus, Hui Yuh Soh, Mariati Abdul Rahman, Xin Peng, Chuanbin Guo, Roszalina Ramli   +5 more
doaj   +1 more source

Assessing the ability of large language models to summarize and generate maxillofacial prosthetic treatment options

Journal of Prosthodontics, EarlyView.
Abstract Purpose The aim was to evaluate the ability of four large language models (LLMs) (OpenAI's ChatGPT‐3.5, Microsoft 365 Copilot, DeepSeek‐R1, and Google Gemini 2.5 Pro) to develop treatment options when presented with clinical cases published in the maxillofacial prosthodontics literature.
Leila M. Sears, Merve Koseoglu, Stavroula Antonopoulou, Sarah Kay Youny Lee, Michael Kase, Amanda Colebeck, Yu‐Chun (Jessie) Lin, Heidi Huber, Maribeth Krzesinski, Alvin G. Wee, Cortino Sukotjo   +10 more
wiley   +1 more source